Clinical Characteristics and Prognosis of Patients with Non-Hodgkin Lymphoma Complicated by Hypercalcemia.
10.19746/j.cnki.issn.1009-2137.2025.04.014
- Author:
Ying LIN
1
;
Rong-Dong ZHANG
1
;
Zeng-Hua LIN
2
;
Xin-Yu XU
3
;
Ren-Li CHEN
1
Author Information
1. School of Clinical Medicine, Fujian Medical University, Fuzhou 350000, Fujian Province, China.
2. Department of Hematology, Affiliated Hospital of Nantong University, Nantong 226001, Jiangsu Province, China.
3. Department of Hematology, Ningde Municipal Hospital of Ningde Normal University, Ningde 352100, Fujian Province, China.
- Publication Type:Journal Article
- Keywords:
non-Hodgkin lymphoma;
hypercalcemia;
clinical characteristics;
treatment;
prognosis
- MeSH:
Humans;
Hypercalcemia/complications*;
Lymphoma, Non-Hodgkin/diagnosis*;
Prognosis;
Retrospective Studies;
Female;
Male;
Middle Aged;
Adult;
Aged;
Calcium/blood*
- From:
Journal of Experimental Hematology
2025;33(4):1029-1035
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To analyze the clinical characteristics, treatment effect and prognosis of patients with non-Hodgkin lymphoma (NHL) complicated by hypercalcemia.
METHODS:The clinical features, treatment and prognosis of 47 patients with NHL complicated by hypercalcemia in Ningde Municipal Hospital of Ningde Normal University and Affiliated Hospital of Nantong University from January 2018 to January 2023 were retrospectively analyzed.
RESULTS:Among the 47 lymphoma patients, 33 cases were T-cell NHL, 14 cases were B-cell NHL. The median serum calcium level of the 47 patients was 3.10 (2.77-4.86) mmol/L, with 27 cases (57.4%) experiencing mild hypercalcemia (2.75-3.00 mmol/L), 8 cases (17.0%) experiencing moderate hypercalcemia (3.00-3.50 mmol/L), and 12 cases (25.5%) experiencing severe hypercalcemia (>3.50 mmol/L). All 47 patients were treated with hydration, alkalization, diuresis, etc. 32 cases (68.1%) received combination chemotherapy, 21 cases (44.7%) received salmon calcitonin treatment, and 3 cases were treated with denosumab in 5 patients with renal insufficiency. After treatment, 38 patients' serum calcium gradually returned to normal, with a median recovery time of 6 (1-18) days, while 9 patients still failed to recover their serum calcium after treatment and all died within 1 month. 32 patients undergoing combination chemotherapy were evaluated for efficacy after 2-4 courses of chemotherapy. Among them, 8 cases (25.0%) achieved complete response (CR), 11 cases (34.4%) achieved partial response (PR), 7 cases (21.9%) showed stable disease (SD), and 6 cases (18.8%) showed progressive disease (PD). The median follow-up time was 10 months. There were 13 cases of disease progression after combination chemotherapy and a total of 28 deaths. The survival time ranged from 0.8 to 23.7 months, and the median progression time was 4.9 months. Multivariate Cox regression analysis showed that the T-cell NHL, blood calcium >3.5 mmol/L, and no decrease in blood calcium after treatment were independent risk factors for the OS, and the T-cell NHL was independent risk factors for the PFS.
CONCLUSION:NHL complicated by hypercalcemia has a poor prognosis, and hypercalcemia can be used as one of the indicators reflecting the tumor burden. Patients with NHL complicated by hypercalcemia should be given more clinical attention and treated actively.
